Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Anlotinib Capsules for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)/Progressive Fibrosis-interstitial Lung Disease (PF-ILDs)
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Interstitial lung diseases; Pulmonary fibrosis
- Focus Therapeutic Use
- 11 Sep 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 28 Apr 2023 New trial record